PolyPid (NASDAQ:PYPD – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.
A number of other brokerages also recently issued reports on PYPD. HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of PolyPid in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a report on Friday, September 18th. Craig Hallum set a $12.00 target price on PolyPid in a research report on Wednesday, July 22nd. Finally, Oppenheimer began coverage on PolyPid in a research report on Tuesday, October 27th. They set an “outperform” rating and a $10.00 target price for the company. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.67.
Check Out Our Latest Report on PolyPid
PolyPid Price Performance
PYPD stock opened at $6.26 on Friday. PolyPid has a fifty-two week low of $3.50 and a fifty-two week high of $7.15. The stock has a market capitalization of $119.46 million, a price-to-earnings ratio of -4.64 and a beta of 1.43. The business’s fifty day moving average price is $5.37 and its two-hundred day moving average price is $4.80.
PolyPid (NASDAQ:PYPD – Get Free Report) last announced its earnings results on Wednesday, November 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.91 by ($1.15). The firm had revenue of $30.00 million for the quarter, compared to the consensus estimate of $30.00 million. Research analysts expect that PolyPid will post -0.92 EPS for the current year.
Institutional Trading of PolyPid
Hedge funds and other institutional investors have recently modified their holdings of the stock. AIGH Capital Management LLC bought a new stake in shares of PolyPid in the 2nd quarter valued at about $7,644,000. ADAR1 Capital Management LLC bought a new position in shares of PolyPid during the second quarter worth about $528,000. Symmetry Peak Management LLC bought a new position in shares of PolyPid during the second quarter worth about $512,000. J. Goldman & Co LP bought a new position in shares of PolyPid during the second quarter worth about $504,000. Finally, Marshall Wace LLP raised its position in shares of PolyPid by 73.7% during the third quarter. Marshall Wace LLP now owns 199,745 shares of the company’s stock worth $1,053,000 after acquiring an additional 84,731 shares during the last quarter. Institutional investors own 26.47% of the company’s stock.
PolyPid Company Profile
PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing products designed to deliver medicines locally and over an extended period. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology is intended to control the release of drugs at the site where they are administered. The company’s lead product candidate, D-PLEX100, uses the antibiotic doxycycline and is designed to be applied during surgery to provide sustained local drug delivery for the prevention of surgical-site infections.
See Also
- Five stocks we like better than PolyPid
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
